Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.

Barbra A Dickerman Hanna Gerlovin Arin L Madenci Katherine E KurganskyBrian R FerolitoMichael J Figueroa MuñizDavid R GagnonJ Michael GazianoKelly ChoJuan P CasasMiguel A Hernán

Published in: The New England journal of medicine (2021)

The 24-week risk of Covid-19 outcomes was low after vaccination with mRNA-1273 or BNT162b2, although risks were lower with mRNA-1273 than with BNT162b2. This pattern was consistent across periods marked by alpha- and delta-variant predominance. (Funded by the Department of Veterans Affairs and others.).

Keyphrases

binding protein
coronavirus disease
sars cov
randomized controlled trial
adipose tissue
tertiary care
insulin resistance
climate change
placebo controlled